Last reviewed · How we verify
Butanefrine (ethylnorepinephrine)
Butanefrine (generic name: ethylnorepinephrine) is a drug. It is currently in unknown development for Acute exacerbation of asthma, Asthma, Asthma management.
Butanefrine works by stimulating the body's natural responses to constrict blood vessels and increase airway resistance.
Butanefrine is a small molecule medication that activates both α and β adrenergic receptors. It is a sympathomimetic and bronchodilator medication related to norepinephrine, sold under various brand names including Etanor, Bronkephrine, and Butanefrine.
At a glance
| Generic name | ethylnorepinephrine |
|---|---|
| Therapeutic area | Respiratory |
| Phase | unknown |
Mechanism of action
Imagine your airways are like a narrow road that needs to be widened to let air pass through. Butanefrine helps to constrict the surrounding blood vessels, which reduces blood flow to the area and allows the airway to open up, making it easier to breathe.
Approved indications
- Acute exacerbation of asthma
- Asthma
- Asthma management
- Bronchiectasis
- Bronchitis
- Pulmonary emphysema
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Butanefrine CI brief — competitive landscape report
- Butanefrine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Butanefrine
What is Butanefrine?
How does Butanefrine work?
What is Butanefrine used for?
What is the generic name of Butanefrine?
What development phase is Butanefrine in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Acute exacerbation of asthma
- Indication: Drugs for Asthma
- Indication: Drugs for Asthma management
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing